Advertisement


Bobbie J. Rimel, MD, Isabelle L. Ray-Coquard, MD, PhD, on Cervical Squamous Carcinoma: Neoadjuvant Nivolumab Plus Ipilimumab

2023 ASCO Annual Meeting

Advertisement

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Isabelle L. Ray-Coquard, MD, PhD, of Centre Léon Bérard and the University Claude Bernard Lyon Est, discuss findings from the COLIBRI trial, which showed that, for patients with cervical squamous cell carcinoma, neoadjuvant nivolumab plus ipilimumab is safe and orchestrates de novo immune responses. The 82.5% complete response rate for primary tumors 6 months after standard chemoradiation therapy suggests favorable clinical outcomes (Abstract 5501). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Bobbie Rimel: Good morning, Dr. Ray-Coquard. Thank you so much for joining me today, and congratulations on the COLIBRI study. Would you mind telling me a little bit about the design of the study, and how you chose to sequence the drugs this way? Isabelle Ray-Coquard: Thank you so much to learn about COLIBRI trial. We are very exciting by such trial. As you understand, it's not a trial dedicated to change routine practice, but to understand what's happened when we use immunotherapy in cervical cancer, and more particularly in locally advanced cervical cancer. The idea is really to explore the double checkpoint inhibition, nivolumab plus ipilimumab, just before to start standard radio chemotherapy. Then to use a six months of maintenance therapy, to continue to include an immune response after radiotherapy. We would like, really, to understand two points. Our double checkpoint inhibition is able to change something in the micro environment of cervical cancer, and e-sequencing immunotherapy and radiotherapy can be better. That what we have seen, particularly with the results of the CALLA trial. Bobbie Rimel: Yeah. I think it's really striking, in the trial, that despite having a neoadjuvant immunotherapy section, that everyone was able to receive radiation, and there were no significant toxicities. Were you surprised by the safety profile of the trial? Isabelle Ray-Coquard: I would say no, because we try to work a lot before, and we just include one cycle of ipilimumab before radiotherapy, that it is, I'm thinking, totally easy. The safety profile right now, as you mentioned, is very good. Also, during the RTCT, and after, during the maintenance therapy, we see very few treatment related that adverse event. For sure, we need to wait for more long follow-up, to be sure about what we are seeing today, but the first signal is very good. The other point is that starting immunotherapy before radiotherapy, during these months, did not change anything. We see six patients, in partial response, after one month of immunotherapy. It's something really interesting for the patients. Bobbie Rimel: Very interesting for the patients. I noticed that there were about 25% of patients, who had a planned secondary biopsy, that were unable to undergo that biopsy. The reason cited was that they were concerned about having undergoing a painful procedure. Since this is such a critical translational endpoint, what are your thoughts for future studies about how to encourage, or help, patients participate in these critical biopsies? Isabelle Ray-Coquard: I'm not sure I will move in this setting in the future, for two reasons. You're right. Painful process never do to be proposed to the patient. What we have seen right now, in COLIBRI, is that on the 27 tumor biopsy we obtain, there is no tumor cell for 26. That mean that, probably, this biopsy, just after RTCT, is not so interesting. What we are doing, right now, we are correlating the systemic immune response and the results. If we are able to correlate immune systemic response, for the future, we will continue with blood sample, and we definitively avoid this biopsy just after RTCT, because of the painful process. Bobbie Rimel: Understood. Where do you think this data is going to fit, in the design of future, larger studies? Isabelle Ray-Coquard: I'm sure. I'm sure, because what we have report with the COLIBRI trial is that it is safe, acceptable for the patient, easy to run. I'm pretty sure that it is the good model for the researcher, the clinician, but also the pharma company, to move in such design, where we would like to explore, which could be the best combination of the best drug we have to explore in cervical cancer. I hope that this kind of trial, we will be very helpful to win time, and also to avoid the huge issue that we have when we include more than 400 patients in a Phase 3, with at the end we see negative results. It is really, the key message of this trial, we can do better, shorter, and easy for the patient. Bobbie Rimel: I think you're making some excellent points. Thank you so much for joining me today, and congratulations on your trial. Isabelle Ray-Coquard: Thank you very much.

Related Videos

Bladder Cancer

Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib and Cetrelimab From the NORSE Study

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses the combination of erdafitinib and cetrelimab, which demonstrated clinically meaningful activity and was well tolerated in cisplatin-ineligible patients with metastatic urothelial carcinoma and fibroblast growth factor receptor alterations (Abstract 4504).

Skin Cancer
Immunotherapy

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Results From CheckMate 358 on Nivolumab With or Without Ipilimumab

Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses phase I/II results on the efficacy of nivolumab with or without ipilimumab in patients with recurrent or metastatic Merkel cell carcinoma. The study found that, for this rare and aggressive skin cancer, nivolumab showed clinical activity in advanced disease. However, these results from CheckMate 358 do not suggest an additional benefit with ipilimumab added to nivolumab (Abstract 9506).

 

Colorectal Cancer

Smitha Krishnamurthi, MD, and Deb Schrag, MD, MPH, on Rectal Cancer: New Findings on Chemoradiation, Chemotherapy, and Excision

Smitha Krishnamurthi, MD, of the Cleveland Clinic, and Deb Schrag, MD, MPH, of Memorial Sloan Kettering Cancer Center, discuss phase III findings from the PROSPECT trial, which showed FOLFOX chemotherapy with selective use of radiation therapy and sensitizing fluoropyrimidine (5FUCRT) is noninferior to 5FUCRT for the neoadjuvant treatment of patients with locally advanced rectal cancer, prior to low anterior resection with total mesorectal excision (Abstract LBA2).

Kidney Cancer
Immunotherapy

Rana R. McKay, MD, and Brian I. Rini, MD, on Clear Cell RCC: New Data From KEYNOTE-426 on Pembrolizumab Plus Axitinib vs Sunitinib

Rana R. McKay, MD, of the University of California, San Diego, and Brian I. Rini, MD, of Vanderbilt-Ingram Cancer Center, discuss the 5-year follow-up results with the combination of a checkpoint inhibitor plus a VEGFR tyrosine kinase inhibitor as first-line treatment for patients with advanced clear cell renal cell carcinoma (RCC). Pembrolizumab plus axitinib continued to demonstrate improved survival outcomes as well as overall response rate vs sunitinib for patients with previously untreated disease (Abstract LBA4501).

Bladder Cancer

Christian Pfister, MD, PhD, on Bladder Cancer: New Overall Survival Data on Perioperative Chemotherapy

Christian Pfister, MD, PhD, of Rouen University Hospital, discusses phase III results from the VESPER trial, which showed that dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin provided a better overall survival rate at 5 years and improved disease-specific survival compared with gemcitabine as perioperative chemotherapy in patients with muscle-invasive bladder cancer (Abstract LBA4507). 

Advertisement

Advertisement




Advertisement